Daré Bioscience CEO to Participate in Maxim Group’s Leading Innovators in Women’s Health Virtual Conference
Daré Bioscience (NASDAQ: DARE) announced that Sabrina Martucci Johnson, President and CEO, will join a panel at Maxim Group's M-Vest Virtual Conference on August 13, 2020, at 10:00 a.m. ET. The discussion, moderated by Jason McCarthy, PhD, focuses on innovations in women's health. Daré is dedicated to advancing women's health through innovative product development, with a clinical-stage portfolio that includes Ovaprene®, Sildenafil Cream, DARE-BV1, and DARE-HRT1. For event registration and details, visit https://bit.ly/2DlgeRW.
- None.
- None.
SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will participate in a panel discussion during Maxim Group’s M-Vest Virtual Conference Series: Leading Innovators in Women’s Health, beginning at 10:00 a.m. Eastern Time on Thursday, August 13, 2020.
The panel will be moderated by Jason McCarthy, PhD, Senior Managing Director and lead biotechnology analyst at Maxim Group.
For additional information on the event, or to register for the webinar, please visit https://bit.ly/2DlgeRW.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.
Daré’s clinical-stage product portfolio includes potential first-in-category candidates in clinical development: Ovaprene®, a hormone-free, monthly contraceptive intravaginal ring whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream,
Daré may announce material information about its finances, product candidates, clinical trials and other matters using its investor relations website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts on its investor relations website (https://darebioscience.gcs-web.com/) and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted on the investor relations page of Daré’s website mentioned above.
Contact:
Investors on behalf of Daré Bioscience, Inc.:
Lee Roth
Burns McClellan
lroth@burnsmc.com
212.213.0006
Source: Daré Bioscience
FAQ
What is the date and time of Daré Bioscience's panel discussion at Maxim Group's conference?
Who is moderating the panel discussion featuring Daré Bioscience's CEO?
What company is participating in the Maxim Group's M-Vest Virtual Conference?
What is the focus of Daré Bioscience's product development?
How can I register for the Maxim Group conference featuring Daré Bioscience?
